Profusa Pipeline | Commercialization Roadmap 2025–2030 | NASDAQ: PFSA
Profusa / Pipeline

Multiple Near-Term Catalysts. A Clear Path to $200–250M Revenue by 2030.

Profusa's commercialization is progressing on three parallel tracks. Each track builds on the same platform, manufacturing infrastructure, and distribution network.

Commercialization Roadmap

Program-by-Program Roadmap

Program Q4 2025 – Q2 2026 Q3 2026 – Q4 2026 Q1 2027 – Q2 2027 Q3 2027+
Research & Government Revenue Begins Q2 2026 Ongoing Revenue Ongoing Revenue Ongoing Revenue
Lumee™ Oxygen (EU) CE Mark + anticipated EU launch EU Revenue Grows EU Revenue Grows EU Revenue Grows
Lumee™ Oxygen (US) Pivotal Study Begins FDA Submission US Revenue Launch US Revenue Grows
Mayo Clinic Collaboration Planning Product Development US Revenue Launch US Revenue Grows
Lumee™ Glucose Data Published + Pivotal Planning CE/FDA Submission Approval Process Glucose Revenue Begins
Operational Pillars

Six Pillars Driving Revenue

AI & Data Science
NVIDIA AI collaboration active

AI-driven data algorithm in development

Physician decision portal planned
Revenue / Commercial
Lumee Oxygen in EU and US

Healthcare Research

Mayo Clinic Collaboration

Lumee Glucose in US and EU
Finance / Resources
$22M PIPE ($12M drawn)

$100M ELOC ($5M drawn)
Regulatory / Clinical
EU MDR CE Mark

US FDA Pivotal Study — 2026

Glucose CE/FDA — 2027
Manufacturing / Operations
Sensor lab certified & online

Excess manufacturing capacity ready

Reader outsourced mfg confirmed
Future Analytes
Lactate

CO₂

Sodium

Ethanol